Pfizer Inc. (NYSE:PFE) closed at $28.40 on2. The stock has returned almost 4% during the last six months, compared to a 21.25 ...
On CNBC’s “Halftime Report Final Trades,” Stephen Weiss, chief investment officer and managing partner of Short Hills Capital ...
Pfizer is deeply unloved, and for good reason, but don't count this drug maker out just yet.
Pfizer Inc. (NYSE:PFE) trades at a considerable discount to AbbVie Inc. (NYSE:ABBV), despite both companies reporting growth ...
Ten consecutive earnings beats and a shrinking COVID hangover have Wall Street split on whether Pfizer deserves a breakout or ...
The Investment Committee gives you their top stocks to watch for the second half.
Pfizer's financial results haven't been great, and upcoming patent cliffs could exacerbate the problem. However, the company's large pipeline across multiple lucrative areas could allow it to bounce ...
Pfizer (PFE) is currently navigating a critical transition period between its old and new growth drivers. Its low price-to-earnings ratio and high dividend yield reflect both opportunity and ...
Insider transactions were seen across major firms this week, including Microsoft (MSFT) and Meta (META). The following trades took place between August 3 and August 7. Executives at Microsoft and Meta ...
Pfizer stock stood at EUR 24.74 on October 8, 2026 after EUR 24.99, down 1.00 percent. Market value was USD 158.1 billion, ...
Pfizer stock trades pre-market at EUR 26.17 at Lang & Schwarz at 8:15 a.m. CEST on October 16, 2026. Based on the Xetra close ...
One of the reasons Pfizer is lagging the market is that its financial results haven't been great in recent years. Over the past three years, the company's top-line growth average has been negative.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results